Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
Machelart, Arnaud Salzano, Giuseppina Li, Xue Demars, Aurore Debrie, Anne-Sophie Menendez-Miranda, Mario Pancani, Elisabetta Jouny, Samuel Hoffmann, Eik Deboosere, Nathalie Belhaouane, Imene Rouanet, Carine Simar, Sophie Talahari, Smail Giannini, Valerie Villemagne, Baptiste Flipo, Marion Brosch, Roland Nesslany, Fabrice Deprez, Benoit Muraille, Eric Locht, Camille Baulard, Alain R Willand, Nicolas Majlessi, Laleh Gref, Ruxandra Brodin, Priscille
ACS Nano, 2019-4-23
https://doi.org/10.1021/acsnano.8b07902
Arnaud Machelart
Machelart Arnaud
ORCID: 0000-0002-4444-0011
Identification of immune effectors essential to the control of primary and secondary intranasal infection with brucella melitensis in mice 10.4049/jimmunol.1502265
In situ characterization of splenic brucella melitensis reservoir cells during the chronic phase of infection in susceptible mice 10.1371/journal.pone.0137835
Brucella melitensis invades murine erythrocytes during infection. 10.1128/iai.01779-14
In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice 10.1371/journal.ppat.1002575
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
Erythritol availability in bovine, murine and human models highlights a potential role for the host aldose reductase during Brucella infection 10.3389/fmicb.2017.01088
Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Chronic Brucella infection induces selective and persistent IFN-γ-dependent alterations of marginal zone macrophages in the spleen. 10.1128/iai.00115-17
Proteomics of Mycobacterium infection: Moving towards a better understanding of pathogen-driven immunomodulation 10.3389/fimmu.2018.00086
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-018-25177-2
Allergic asthma favors Brucella growth in the lungs of infected mice 10.3389/fimmu.2018.01856
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis 10.1021/acsnano.8b07902
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Route of Infection Strongly Impacts the Host-Pathogen Relationship 10.3389/fimmu.2019.01589
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Occurrence and repair of alkylating stress in the intracellular pathogen Brucella abortus 10.1038/s41467-019-12516-8
Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity 10.1021/acsinfecdis.9b00277
Convergent evolution of zoonoticBrucellaspecies toward the selective use of the pentose phosphate pathway 10.1073/pnas.2008939117
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies 10.3389/fimmu.2020.569127
SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota 10.1080/19490976.2021.1893113
Trypanosoma infection favors Brucella elimination via IL-12/IFNγ-dependent pathways 10.3389/fimmu.2017.00903
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483
High-Content Analysis Monitoring Intracellular Trafficking and Replication of Mycobacterium tuberculosis Inside Host Cells 10.1007/978-1-0716-1460-0_29
Eik Hoffmann
Hoffmann Eik
ORCID: 0000-0003-4224-1091
Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005
Evaluation of Cross-presentation in Bone Marrow-derived Dendritic Cells in vitro and Splenic Dendritic Cells ex vivo Using Antigen-coated Beads. 10.21769/BioProtoc.2015
Patterns, Receptors, and Signals: Regulation of Phagosome Maturation. 10.1016/j.it.2017.03.006
Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages. 10.1016/j.immuni.2016.02.017
Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens. 10.1016/j.immuni.2015.11.006
Autonomous phagosomal degradation and antigen presentation in dendritic cells. 10.1073/pnas.1203912109
Reactive oxygen species production in the phagosome: impact on antigen presentation in dendritic cells. 10.1089/ars.2012.4557
Comparison of micro- and nanoscale Fe⁺³-containing (Hematite) particles for their toxicological properties in human lung cells in vitro. 10.1093/toxsci/kfs014
Titanium dioxide nanoparticles induce oxidative stress and DNA-adduct formation but not DNA-breakage in human lung cells. 10.1186/1743-8977-6-17
The unfolded-protein-response sensor IRE-1α regulates the function of CD8α+ dendritic cells. 10.1038/ni.2808
Synthesis of the compatible solutes glucosylglycerol and trehalose by salt-stressed cells of Stenotrophomonas strains. 10.1016/j.femsle.2004.12.005
Ezrin promotes actin assembly at the phagosome membrane and regulates phago-lysosomal fusion. 10.1111/j.1600-0854.2011.01158.x
Initial receptor-ligand interactions modulate gene expression and phagosomal properties during both early and late stages of phagocytosis. 10.1016/j.ejcb.2010.04.006
Sphingosine-1-phosphate receptors stimulate macrophage plasma-membrane actin assembly via ADP release, ATP synthesis and P2X7R activation. 10.1242/jcs.034207
Dynamin A, Myosin IB and Abp1 couple phagosome maturation to F-actin binding. 10.1111/j.1600-0854.2011.01296.x
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017
Proteomics of Mycobacterium Infection: Moving towards a Better Understanding of Pathogen-Driven Immunomodulation 10.3389/fimmu.2018.00086
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Spatiotemporal changes of the phagosomal proteome in dendritic cells in response to LPS stimulation 10.1074/mcp.RA119.001316
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies 10.3389/fimmu.2020.569127
High-Content Analysis Monitoring Intracellular Trafficking and Replication of Mycobacterium tuberculosis Inside Host Cells 10.1007/978-1-0716-1460-0_29
The UPR sensor IRE1α promotes dendritic cell responses to control Toxoplasma gondii infection 10.15252/embr.201949617
Elisabetta Pancani
Pancani Elisabetta
ORCID: 0000-0001-8649-9110
Erratum: Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles (Scientific reports (2017) 7 1 (5390)) 10.1038/s41598-018-25177-2
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis 10.1021/acsnano.8b07902
Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Conventional versus stealth lipid nanoparticles: Formulation and in vivo fate prediction through FRET monitoring 10.1016/j.jconrel.2014.05.042
Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach 10.1016/j.apsb.2018.03.008
High-Resolution Label-Free Detection of Biocompatible Polymeric Nanoparticles in Cells 10.1002/ppsc.201700457
Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization 10.1016/j.ijpharm.2017.05.041
How to unravel the chemical structure and component localization of individual drug-loaded polymeric nanoparticles by using tapping AFM-IR 10.1039/c8an01239c
Eric Muraille
Muraille Eric
ORCID: 0000-0003-1250-5228
Carbohydrate-bearing cell surface receptors involved in innate immunity: Interleukin-12 induction by mitogenic and nonmitogenic lectins 10.1006/cimm.1998.1401
Amastigote load and cell surface phenotype of infected cells from lesions and lymph nodes of susceptible and resistant mice infected with Leishmania major 10.1128/IAI.71.5.2704-2715.2003
Endogenous interleukin-12 is critical for controlling the late but not the early stage of Leishmania mexicana infection in C57BL/6 mice 10.1128/IAI.70.9.5075-5080.2002
In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice 10.1371/journal.ppat.1002575
Redefining the Immune System as a Social Interface for Cooperative Processes 10.1371/journal.ppat.1003203
The SH2 domain containing inositol 5-phosphatase SHIP2 associates to the immunoreceptor tyrosine-based inhibition motif of FcγRIIB in B cells under negative signaling 10.1016/S0165-2478(00)00162-0
Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo 10.1084/jem.184.4.1413
The nonspecific face of adaptive immunity 10.1016/j.coi.2017.08.002
Role and regulation of IL-12 in the in vivo response to staphylococcal enterotoxin B 10.1093/intimm/11.9.1403
In situ characterization of splenic brucella melitensis reservoir cells during the chronic phase of infection in susceptible mice 10.1371/journal.pone.0137835
Myd88-Dependent In Vivo Maturation of Splenic Dendritic Cells Induced by Leishmania donovani and Other Leishmania Species 10.1128/IAI.72.2.824-832.2004
Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection 10.1111/pim.12344
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response 10.4049/jimmunol.170.8.4237
Trypanosoma infection favors Brucella elimination via IL-12/IFNγ-dependent pathways 10.3389/fimmu.2017.00903
Investigation of inflammatory and allergic responses to common mold species: Results from in vitro experiments, from a mouse model of asthma, and from a group of asthmatic patients 10.1111/ina.12385
Complete genome sequence of the Escherichia coli PMV-1 strain, a model extraintestinal pathogenic E. coli strain used for host-pathogen interaction studies 10.1128/genomeA.e00913-13
MyD88-dependent activation of B220-CD11b+LY-6C + dendritic cells during Brucella melitensis infection 10.4049/jimmunol.178.8.5182
Brucella melitensis invades murine erythrocytes during infection 10.1128/IAI.01779-14
Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens 10.1093/intimm/7.2.295
Erythritol availability in bovine, murine and human models highlights a potential role for the host aldose reductase during Brucella infection 10.3389/fmicb.2017.01088
Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis 10.4049/jimmunol.1302561
Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy 10.1111/j.1398-9995.2008.01825.x
Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway 10.1002/eji.200939913
The SH2 domain-containing 5-phosphatase SHIP2 is expressed in the germinal layers of embryo and adult mouse brain: Increased expression in N-CAM-deficient mice 10.1016/S0306-4522(01)00240-8
iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice 10.1371/journal.ppat.1000494
Distribution of the Src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells 10.1042/0264-6021:3420697
Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKε-dependent lys63-linked polyubiquitination and phosphorylation of TANK/I-TRAF 10.1074/jbc.M701690200
Generation of individual diversity: A too neglected fundamental property of adaptive immune system 10.3389/fimmu.2014.00208
T cell-dependent maturation of dendritic cells in response to bacterial superantigens 10.4049/jimmunol.168.9.4352
The unspecific side of acquired immunity against infectious disease: Causes and consequences 10.3389/fmicb.2015.01525
In vivo characterization of two additional Leishmania donovani strains using the murine and hamster model 10.1111/pim.12316
Th1/Th2 paradigm extended: Macrophage polarization as an unappreciated pathogen-driven escape mechanism? 10.3389/fimmu.2014.00603
Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of cd8+ t cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice 10.1128/IAI.00761-12
Normal development and function of dendritic cells in mice lacking IDO-1 expression 10.1016/j.imlet.2008.02.006
B7.2 provides co‐stimulatory functions in vivo in response to staphylococcal enterotoxin B 10.1002/eji.1830250747
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through toll-like receptor 4 10.1002/eji.200737998
Bacterial c-di-GMP is an immunostimulatory molecule 10.4049/jimmunol.178.4.2171
Distinct in vivo dendritic cell activation by live versus killed Listeria monocytogenes 10.1002/eji.200526024
Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation 10.1006/cimm.1995.1084
Toxicity and neuroendocrine regulation of the immune response: A model analysis 10.1006/jtbi.1996.0221
Glucocorticoids down‐regulate dendritic cell function in vitro and in vivo 10.1002/eji.1830251016
Identification of immune effectors essential to the control of primary and secondary intranasal infection with brucella melitensis in mice 10.4049/jimmunol.1502265
Direct visualization of peptide/MHC complexes at the surface and in the intracellular compartments of cells infected In Vivo by Leishmania major 10.1371/journal.ppat.1001154
Cytosolic expression of SecA2 is a prerequisite for long-term protective immunity 10.1111/j.1462-5822.2007.00883.x
Route of infection strongly impacts the host-pathogen relationship 10.3389/fimmu.2019.01589
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis 10.1021/acsnano.8b07902
Allergic asthma favors Brucella growth in the lungs of infected mice 10.3389/fimmu.2018.01856
STAT6 mediates footpad immunopathology in the absence of IL-12p40 following infection of susceptible BALB/c mice with Leishmania major 10.3389/fimmu.2018.00503
Diversity generator mechanisms are essential components of biological systems: The two queen hypothesis 10.3389/fmicb.2018.00223
Occurrence and repair of alkylating stress in the intracellular pathogen Brucella abortus 10.1038/s41467-019-12516-8
Ethical control of innovation in a globalized and liberal world: Is good science still science? 10.1016/j.endeavour.2020.100709
Baptiste Villemagne
Villemagne Baptiste
ORCID: 0000-0002-8416-5253
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands 10.1016/j.ab.2014.02.011
Structural and docking studies of potent ethionamide boosters 10.1107/S0108270113028126
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
Tuberculosis: The drug development pipeline at a glance 10.1016/j.ejmech.2012.02.033
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR 10.1016/j.bbapap.2018.12.003
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2. 10.1016/j.ejmech.2019.02.023
Intrinsic Antibacterial Activity of Nanoparticles Made of beta-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity 10.1021/acsinfecdis.9b00277
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
Mario Menendez-Miranda
Menendez-Miranda Mario
ORCID: 0000-0002-2992-1351
Determination of the ratio of fluorophore/nanoparticle for fluorescence-labelled nanoparticles 10.1039/c5an02405f
Asymmetric flow field-flow fractionation coupled to inductively coupled plasma mass spectrometry for the quantification of quantum dots bioconjugation efficiency 10.1016/j.chroma.2015.10.012
Precise determination of the nanoparticle concentration and ligand density of engineered water-soluble HgSe fluorescent nanoparticles 10.1039/c5ra26268b
Highly Porous Hybrid Metal–Organic Nanoparticles Loaded with Gemcitabine Monophosphate: a Multimodal Approach to Improve Chemo- and Radiotherapy 10.1002/cmdc.201900596
Elemental ratios for characterization of quantum-dots populations in complex mixtures by asymmetrical flow field-flow fractionation on-line coupled to fluorescence and inductively coupled plasma mass spectrometry 10.1016/j.aca.2014.06.034
Design of engineered cyclodextrin derivatives for spontaneous coating of highly porous metal-organic framework nanoparticles in aqueous media 10.3390/nano9081103
Mass spectrometry for the characterization and quantification of engineered inorganic nanoparticles 10.1016/j.trac.2016.06.001
Study of conformational changes and protein aggregation of bovine serum albumin in presence of Sb(III) and Sb(V) 10.1371/journal.pone.0170869
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis 10.1021/acsnano.8b07902
Comb-like dextran copolymers: A versatile strategy to coat highly porous MOF nanoparticles with a PEG shell 10.1016/j.carbpol.2019.115085
Green synthesis of fluorescent carbon dots from spices for in vitro imaging and tumour cell growth inhibition 10.3762/bjnano.9.51
Room temperature phosphorimetric determination of bromate in flour based on energy transfer 10.1016/j.talanta.2013.05.019
Isotopically enriched nanoparticles in combination with mass spectrometry for the assessment of nanoparticle-biomolecule stoichiometries in engineered nanoassemblies 10.1016/j.sab.2018.07.019
Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach 10.1016/j.apsb.2018.03.008
Archaeometric analysis of Asturian pottery in XVI-XVII centuries 10.1016/j.bsecv.2019.01.005
Voltammetric determination of size and particle concentration of Cd-based quantum dots 10.1016/j.electacta.2015.03.051
Cyclodextrin-based metal-organic frameworks particles as efficient carriers for lansoprazole: Study of morphology and chemical composition of individual particles 10.1016/j.ijpharm.2017.05.056
Nanostructural transformations of silver nanoclusters occurring during their synthesis and after interaction with UV-light 10.1088/2053-1591/1/1/015039
willand nicolas
nicolas willand
ORCID: 0000-0002-0784-0462
Neuraminidase inhibitors and risk of H5N1 influenza,Les inhibiteurs de neuraminidase face au risque de grippe aviaire 10.1016/s0003-4509(07)90016-4
Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands 10.1016/j.ab.2014.02.011
Water-based conditions for the microscale parallel synthesis of bicyclic lactams 10.1016/j.tetlet.2012.11.082
Exploring drug target flexibility using in situ click chemistry: Application to a mycobacterial transcriptional regulator 10.1021/cb100177g
Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction 10.1016/j.tetlet.2005.12.022
Synthesis of functionalized 2-isoxazolines as three-dimensional fragments for fragment-based drug discovery 10.1016/j.tetlet.2015.05.035
Efficient, two-step synthesis of N-substituted nortropinone derivatives 10.1016/j.tetlet.2007.05.110
Natural compounds: Leads or ideas? Bioinspired molecules for drug discovery 10.1111/j.1747-0285.2008.00673.x
MALDI imaging techniques dedicated to drug-distribution studies 10.4155/bio.11.88
Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728 10.1016/S0040-4020(02)00536-7
Original loading and Suzuki conditions for the solid-phase synthesis of biphenyltetrazoles. Application to the first solid-phase synthesis of irbesartan 10.1016/j.tetlet.2008.02.147
Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation 10.1016/j.ejmech.2011.05.056
A simple reaction to produce small structurally complex and diverse molecules 10.1016/j.tetlet.2004.05.008
Efficient, protection-free Suzuki-Miyaura synthesis of ortho- biphenyltetrazoles 10.1016/j.tetlet.2005.07.082
Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands 10.1093/nar/gkr1113
Microwave-assisted synthesis of functionalized spirohydantoins as 3-D privileged fragments for scouting the chemical space 10.1016/j.tetlet.2016.05.065
Ethionamide boosters: Synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors 10.1021/jm200076a
Carbohydrate-protein interactions at interfaces: Synthesis of thiolactosyl glycolipids and design of a working model for surface plasmon resonance 10.1039/b210672h
Structural and docking studies of potent ethionamide boosters 10.1107/S0108270113028126
A versatile solid-phase synthesis of 3-aryl-1,2,4-oxadiazolones and analogues 10.1016/j.tetlet.2006.12.050
UFU ('Ullmann-Finkelstein-Ullmann'): a new multicomponent reaction 10.1016/j.tetlet.2006.04.041
Palladium-free Sonogashira-type cross-coupling reaction of bromoisoxazolines or N-alkoxyimidoyl bromides and alkynes 10.1016/j.tetlet.2016.01.070
Tuberculosis: The drug development pipeline at a glance 10.1016/j.ejmech.2012.02.033
Synthesis and structural studies of a novel scaffold for drug discovery: A 4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4′-piperidine] 10.1016/j.tetlet.2003.11.079
Synthetic EthR inhibitors boost antituberculous activity of ethionamide 10.1038/nm.1950
A facile and rapid synthesis of N-benzyl-2-substituted piperazines 10.1016/j.tetlet.2011.02.011
Ligand efficiency driven design of new inhibitors of mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches 10.1021/jm500422b
Discovery of novel N -phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis 10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors 10.1021/jm200825u
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR 10.1016/j.bbapap.2018.12.003
A novel codrug made of the combination of ethionamide and its potentiating booster: Synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/c9ob00680j
Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2 10.1016/j.bbrc.2017.04.074
Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance 10.1016/bs.armc.2019.06.003
New active leads for tuberculosis booster drugs by structure-based drug discovery 10.1039/c7ob00910k
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis 10.1016/j.ejmech.2018.09.038
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis 10.1021/acsnano.8b07902
Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity 10.1021/acsinfecdis.9b00277
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening 10.1016/j.ejmech.2020.112440
Microwave-Assisted Suzuki-Miyaura Cross Coupling using Nickel as Catalyst to Rapidly Access to 3-Arylazetidine 10.1002/slct.201702101
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2 10.1016/j.ejmech.2019.02.023
Marion Flipo
Flipo Marion
ORCID: 0000-0003-2863-5721
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR 10.1016/j.bbapap.2018.12.003
Structural rearrangements occurring upon cofactor binding in the Mycobacterium smegmatis beta-ketoacyl-acyl carrier protein reductase MabA 10.1107/S2059798318002917
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
Microwave-assisted synthesis of functionalized spirohydantoins as 3-D privileged fragments for scouting the chemical space 10.1016/j.tetlet.2016.05.065
Synthesis of functionalized 2-isoxazolines as three-dimensional fragments for fragment-based drug discovery 10.1016/j.tetlet.2015.05.035
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-beta hydrolysis 10.1016/j.ejmech.2014.04.009
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands 10.1016/j.ab.2014.02.011
On the Mechanism of Degradation of Oxytocin and its Analogues in Aqueous Solution 10.1002/bip.22260
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
Structure-Activity Relationships and Blood Distribution of Antiplasmodial Aminopeptidase-1 Inhibitors 10.1021/jm301506h
Tuberculosis: The drug development pipeline at a glance 10.1016/j.ejmech.2012.02.033
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
Hydroxamates: Relationships between Structure and Plasma Stability 10.1021/jm900648x
A library of novel hydroxamic acids targeting the metallo-protease family: Design, parallel synthesis and screening 10.1016/j.bmc.2006.10.010
Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents 10.1021/jm061169b
Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors 10.1016/S0960-894X(03)00550-X
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2 10.1016/j.ejmech.2019.02.023
Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance 10.1016/bs.armc.2019.06.003
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity 10.1021/acsinfecdis.9b00277
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening 10.1016/j.ejmech.2020.112440
Roland Brosch
Brosch Roland
ORCID: 0000-0003-2587-3863
Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity. 10.1016/j.chom.2015.05.017
Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii 10.1093/gbe/evv035
Mycobacterial Pathogenomics and Evolution. 10.1128/microbiolspec.MGM2-0025-2013
Release of mycobacterial antigens 10.1111/imr.12251
Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice 10.1128/IAI.02032-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations 10.1038/srep15443
ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection 10.1016/j.tube.2015.02.019
Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
Bovine tubercle bacilli: evolution associated with loss of transmission capacity in humans | Les bacilles de la tuberculose bovine - Une évolution aux dépens de la transmissibilité chez l'homme 10.1051/medsci/20153102003
Mycobacterium tuberculosis Exploits Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection 10.1371/journal.ppat.1003928
Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development 10.2217/fmb.14.70
Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111
Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy 10.1016/j.eururo.2014.02.061
A Specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whiB6 as a novel ESX-1 component 10.1128/IAI.01824-14
A glimpse into the past and predictions for the future: The molecular evolution of the tuberculosis agent 10.1111/mmi.12720
TBCAP; Tuberculosis annotation project 10.1016/j.tube.2012.11.013
Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus 10.1111/mmi.12387
Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis 10.1038/ng.2517
ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169
Characterization of Mycobacterium orygis 10.3201/eid1903.121005
The ESX-5 Associated eccB5-eccC5 Locus Is Essential for Mycobacterium tuberculosis Viability 10.1371/journal.pone.0052059
Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion-encoded PE-PPE proteins predicts vaccine potential 10.1016/j.chom.2012.03.003
Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death 10.1371/journal.ppat.1002507
Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh 10.1371/journal.pone.0040545
Molecular epidemiology of tuberculosis in rural Matlab, Bangladesh 10.5588/ijtld.11.0426
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria 10.1111/j.1462-5822.2012.01799.x
ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells 10.4161/auto.20881
Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation 10.1111/j.1365-2958.2012.08001.x
Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies 10.3201/eid1804.110888
Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis 10.1002/eji.201141548
p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways 10.1074/jbc.M111.223610
Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants 10.1111/j.1462-5822.2010.01565.x
ESAT-6 secretion-independent impact of ESX-1 genes espF and espG 1on virulence of Mycobacterium tuberculosis 10.1093/infdis/jiq089
Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007
Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring 10.1016/j.ejmech.2010.09.048
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling 10.1371/journal.ppat.1001100
Entrapment of intracytosolic bacteria by septin cage-like structures 10.1016/j.chom.2010.10.009
Systematic genetic nomenclature for type VII secretion systems 10.1371/journal.ppat.1000507
Pathogenomics of mycobacteria 10.1159/000235772
Pathogenicity in the tubercle bacillus: Molecular and evolutionary determinants 10.1002/bies.200800191
Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus 10.1371/journal.pone.0005660
Myths and misconceptions: The origin and evolution of Mycobacterium tuberculosis 10.1038/nrmicro2165
Mycobacterial PE, PPE and ESX clusters: Novel insights into the secretion of these most unusual protein families 10.1111/j.1365-2958.2009.06784.x
High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors 10.1371/journal.ppat.1000645
ESX/type VII secretion systems and their role in host-pathogen interaction 10.1016/j.mib.2008.11.003
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis 10.1101/gr.075069.107
Functional analysis of a clonal deletion in an epidemic strain of Mycobacterium bovis reveals a role in lipid metabolism 10.1099/mic.0.2008/022269-0
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
BCG: Molecular history and new perspectives | Le BCG: Histoire moléculaire et nouvelles perspectives RMR-06-2008-25-00-01761-8425-101019-200806495
Genome plasticity of BCG and impact on vaccine efficacy 10.1073/pnas.0700869104
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/JB.00469-07
Pathogenomics: Insights into Tuberculosis and Related Mycobacterial Diseases 10.1002/352760801X.ch10
Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis 10.1093/molbev/msj120
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/IAI.74.1.88-98.2006
Contribution of mycobacterial genomics to the development of innovative strategies against tuberculosis | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses 10.1016/S1773-035X(06)80148-6
"A re-evaluation of M. prototuberculosis": Continuing the debate 10.1371/journal.ppat.0020095
Tuberculosis: From genome to vaccine 10.1586/14760584.4.4.541
Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against Oxidative Stress 10.1074/jbc.M503076200
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin 10.1111/j.1462-5822.2005.00546.x
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans 10.1128/JB.187.5.1668-1676.2005
Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis 10.1371/journal.ppat.0010005
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans 10.1073/pnas.0305877101
Genotypic Analysis of Mycobacterium tuberculosis in Bangladesh and Prevalence of the Beijing Strain 10.1128/JCM.42.2.674-682.2004
ESAT-6 proteins: Protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
Cell Envelope Protein PPE68 Contributes to Mycobacterium tuberculosis RD1 Immunogenicity Independently of A 10-Kilodalton Culture Filtrate Protein and ESAT-6 10.1128/IAI.72.4.2170-2176.2004
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? [3] (multiple letters) 10.1128/JCM.41.3.1345-1348.2003
Royal society of tropical medicine and hygiene meeting at Manson house, London, 18 January 2001: Pathogen genomes and human health. Mycobacterial genomics 10.1016/S0035-9203(02)90222-1
Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis 10.1128/JCM.40.7.2339-2345.2002
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/IAI.70.10.5568-5578.2002
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
The evolution of mycobacterial pathogenicity: Clues from comparative genomics 10.1016/S0966-842X(01)02131-X
Genomics of Mycobacterium bovis 10.1054/tube.2000.0269
Tools for the population genomics of the tubercle bacilli 10.1101/gr.169200
Comparative genomics of the leprosy and tubercle bacilli 10.1016/S0923-2508(00)00117-0
Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays 10.1046/j.1365-2958.1999.01383.x
Analysis of the proteome of Mycobacterium tuberculosis in silico 10.1054/tuld.1999.0220
The high-pathogenicity island of Yersinia pseudotuberculosis can be inserted into any of the three chromosomal asn tRNA genes 10.1046/j.1365-2958.1998.01124.x
Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence 10.1038/31159
Genomic fingerprinting of 80 strains from the WHO multicenter international typing study of Listeria monocytogenes via pulsed-field gel electrophoresis (PFGE) 10.1016/S0168-1605(96)01147-6
Characterization of Listeria strains isolated from soft cheese 10.1016/0168-1605(93)90220-B
Listeriosis outbreak in France in 1992. Microbial data | Epidémie de listériose en France en 1992 aspects microbiologiques 10.1016/S0399-077X(05)81214-4
Use of pulsed field gel electrophoresis to compare large DNA-restriction fragments of Listeria monocytogenes strains belonging to serogroups 1/2 and 3 10.1016/0168-1605(91)90121-5
Subtyping of Listeria monocytogenes serovar 4b by use of low-frequency-cleavage restriction endonucleases and pulsed-field gel electrophoresis 10.1016/0923-2508(91)90080-T
Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions 10.1038/srep17078
Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis 10.1038/srep16918
Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. 10.1016/j.tube.2010.03.008
The BCG Strain Pool: Diversity Matters. 10.1038/mt.2016.18
Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications. 10.1186/s12864-016-2448-1
Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. 10.1111/cmi.12622
Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria 10.1073/pnas.1604921113
Comparative Genomics and Evolution of Mycobacterium bovis BCG 10.1128/9781555817657.ch10
The Mycobacteria: a Postgenomic View 10.1128/9781555815530.ch3
Genomics ofMycobacterium Tuberculosis and Mycobacterium Leprae 10.1002/9781444311433.ch5
Genomics of the Mycobacterium tuberculosis complex and Mycobacterium leprae 10.1002/047001153x.g205204
ESX secretion systems: mycobacterial evolution to counter host immunity 10.1038/nrmicro.2016.131
Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384 10.1128/aac.02509-16
ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. 10.1111/cmi.12726
Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis 10.1038/mi.2016.140
Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection 10.1016/j.celrep.2017.02.057
PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1006399
Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells 10.1038/s41598-017-05878-w
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Evolution of virulence in the Mycobacterium tuberculosis complex 10.1016/j.mib.2017.11.021
The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis 10.3389/fmicb.2017.02284
Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis 10.1038/s41564-017-0090-6
Discovery of the type VII ESX-1 secretion needle? 10.1111/mmi.13579
Identification of genes required forMycobacterium abscessusgrowth in vivo with a prominent role of the ESX-4 locus 10.1073/pnas.1713195115
Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions 10.1073/pnas.1620133114
Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation 10.1371/journal.ppat.1006752
The Biology and Epidemiology of Mycobacterium canettii 10.1007/978-3-319-64371-7_2
Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs 10.2174/1381612819666131118170717
Taxonomic Diversity of Pseudomonads Revealed by Computer-interpretation of Ribotyping Data 10.1016/s0723-2020(96)80026-9
Comparative genomics of the mycobacteria 10.1016/s1438-4221(00)80083-1
Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens 10.3791/50116
Type VII Secretion Systems in Gram-Positive Bacteria 10.1007/82_2015_5015
Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’ 10.1099/mgen.0.000063
Leprosy in red squirrels 10.1126/science.aal0145
CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection 10.1371/journal.ppat.1005770
pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence 10.1038/nmicrobiol.2015.19
A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence ofMycobacterium marinumin multiple hosts 10.1111/cmi.12606
The PE and PPE Protein Families of Mycobacterium tuberculosis 10.1002/9783527611614.ch7
Influence of ESAT-6 Secretion System 1 (RD1) of Mycobacterium tuberculosis on the Interaction between Mycobacteria and the Host Immune System 10.4049/jimmunol.174.6.3570
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo 10.1172/jci84978
Cutting-edge science and the future of tuberculosis control 10.2471/blt.06.035386
ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13
RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139
Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity 10.1093/gbe/evy145
New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach 10.1016/j.jprot.2018.09.013
Update on the virulence factors of the obligate pathogen Mycobacterium tuberculosis and related tuberculosis-causing mycobacteria 10.1016/j.meegid.2018.12.013
Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis 10.1093/gbe/evz162
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902
Mycobacterial virulence: impact on immunogenicity and vaccine research 10.12688/f1000research.20572.1
TbD1 deletion as a driver of the evolutionary success of modern epidemic Mycobacterium tuberculosis lineages 10.1038/s41467-020-14508-5
Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8
ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins 10.1128/microbiolspec.psib-0029-2019
ESX-4, un système de sécrétion mycobactérien ancestral, essentiel pour la croissance de Mycobacterium abscessus dans les phagocytes environnementaux et humains 10.1051/medsci/2018196
Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages 10.1371/journal.ppat.1008069
A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies 10.1126/sciadv.aaz1767
Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential 10.1016/j.ebiom.2020.102761
Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes 10.1073/pnas.2003235117
Le BCG : histoire moléculaire et nouvelles perspectives 10.1016/s0761-8425(08)56032-3
Breaching the phagosome, the case of the tuberculosis agent 10.1111/cmi.13344
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection 10.7554/elife.55692
IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo 10.1128/mSphere.00153-21
ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains 10.1128/mBio.00965-21
Evolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance 10.1128/microbiolspec.tbtb2-0020-2016
Phthiocerol Dimycocerosates From Mycobacterium tuberculosis Increase the Membrane Activity of Bacterial Effectors and Host Receptors 10.3389/fcimb.2020.00420
Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli 10.1038/s41564-021-00938-4
Aurore Demars
Demars Aurore
ORCID: 0000-0002-7978-6880
Chronic Brucella Infection Induces Selective and Persistent Interferon Gamma-Dependent Alterations of Marginal Zone Macrophages in the Spleen. 10.1128/iai.00115-17
Trypanosoma Infection Favors Brucella Elimination via IL-12/IFNγ-Dependent Pathways. 10.3389/fimmu.2017.00903
Route of Infection Strongly Impacts the Host-Pathogen Relationship. 10.3389/fimmu.2019.01589
Shedding of Brucella melitensis happens through milk macrophages in the murine model of infection. 10.1038/s41598-020-65760-0
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902
Allergic Asthma Favors Brucella Growth in the Lungs of Infected Mice. 10.3389/fimmu.2018.01856
Summary of the Sussex-Huawei locomotion-transportation recognition challenge
Observation of a manifold in the chaotic phase space of an asymmetric optical microcavity
Localized temporal variation of Earth's inner-core boundary from high-quality waveform doublets
Off-axis multi-wavelength dispersion controlling metalens for multi-color imaging
Impact of United States political sanctions on international collaborations and research in Iran